Quarterly report [Sections 13 or 15(d)]

NON CONTROLLING INTEREST (Details)

v3.25.3
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Net loss $ (808,502) $ 1,377,276 $ 851,764 $ (1,513,010) $ (1,233,996) $ (1,237,463) $ (3,037,545) $ (3,984,469)
Net loss attributable to the non-controlling interest (1,109,371)     25,623     (955,156) 42,960
BioCorRx Pharmaceuticals, Inc [Member]                
Net loss $ (1,917,873)     $ (106,233)     $ (3,992,701) $ (175,033)
Average Non-controlling interest percentage of profit/losses 2420.00%     24.20%     24.20% 24.20%
Net loss attributable to the non-controlling interest $ (464,126)     $ (25,708)     $ (966,233) $ (42,358)
Joseph DeSanto MD [Member]                
Net loss $ (13)     $ 244     $ (15) $ (1,720)
Average Non-controlling interest percentage of profit/losses 3500.00%     35.00%     35.00% 35.00%
Net loss attributable to the non-controlling interest $ (5)     $ 85     $ (5) $ (602)